AMNEAL PHARMACEUTICALS, INC. Proceeds from Lines of Credit
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Proceeds from Lines of Credit of $100.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2026-08-06
- AMNEAL PHARMACEUTICALS, INC. proceeds from lines of credit for the quarter ending 2026-06-30 was $100.00M.
- AMNEAL PHARMACEUTICALS, INC. proceeds from lines of credit for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. proceeds from lines of credit for the quarter ending 2025-12-31 was $0.00.
- AMNEAL PHARMACEUTICALS, INC. proceeds from lines of credit for the quarter ending 2025-09-30 was $0.00.
- AMNEAL PHARMACEUTICALS, INC. proceeds from lines of credit for fiscal 2025 was $218.00M, a 354.17% increase from fiscal 2024.
- AMNEAL PHARMACEUTICALS, INC. proceeds from lines of credit for fiscal 2024 was $48.00M, a 78.08% decline from fiscal 2023.
- AMNEAL PHARMACEUTICALS, INC. proceeds from lines of credit for fiscal 2023 was $219.00M, a 157.65% increase from fiscal 2022.
- AMNEAL PHARMACEUTICALS, INC. proceeds from lines of credit for fiscal 2022 was $85.00M.
| Period end | Proceeds from Lines of Credit 3 month | Proceeds from Lines of Credit 6 month | Proceeds from Lines of Credit 9 month | Proceeds from Lines of Credit 12 month |
|---|---|---|---|---|
| 2026-06-30 | $100.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $100.00M 10-Q · filed 2026-08-06 | $100.00M derived: sum of 3 quarters · filed 2026-08-06 | $100.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $0.00 derived: sum of 3 quarters · filed 2026-05-07 | $0.00 derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 derived: sum of 2 quarters · filed 2026-02-27 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $218.00M 10-K · filed 2026-02-27 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | $218.00M 10-Q · filed 2025-11-06 | $218.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $218.00M 10-Q · filed 2026-08-06 | $218.00M derived: sum of 3 quarters · filed 2026-08-06 | $218.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $218.00M 10-Q · filed 2026-05-07 | $218.00M derived: sum of 2 quarters · filed 2026-05-07 | $218.00M derived: sum of 3 quarters · filed 2026-05-07 | $218.00M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 derived: sum of 2 quarters · filed 2026-02-27 | $0.00 derived: sum of 3 quarters · filed 2026-02-27 | $48.00M 10-K · filed 2026-02-27 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $48.00M 10-Q · filed 2025-11-06 | $157.00M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $48.00M 10-Q · filed 2025-08-07 | $157.00M derived: sum of 3 quarters · filed 2026-02-27 | $167.00M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $48.00M 10-Q · filed 2025-05-07 | $157.00M derived: sum of 2 quarters · filed 2026-02-27 | $167.00M derived: sum of 3 quarters · filed 2026-02-27 | $187.00M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $109.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $119.00M derived: sum of 2 quarters · filed 2026-02-27 | $139.00M derived: sum of 3 quarters · filed 2026-02-27 | $219.00M 10-K · filed 2026-02-27 |
| 2023-09-30 | $10.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $30.00M derived: sum of 2 quarters · filed 2024-11-12 | $110.00M 10-Q · filed 2024-11-12 | $110.00M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $20.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $100.00M 10-Q · filed 2024-08-09 | $100.00M derived: sum of 3 quarters · filed 2025-02-28 | $100.00M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $80.00M 10-Q · filed 2024-05-08 | $80.00M derived: sum of 2 quarters · filed 2025-02-28 | $80.00M derived: sum of 3 quarters · filed 2025-02-28 | $165.00M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $0.00 derived: sum of 2 quarters · filed 2025-02-28 | $85.00M derived: sum of 3 quarters · filed 2025-02-28 | $85.00M 10-K · filed 2025-02-28 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $85.00M derived: sum of 2 quarters · filed 2023-11-09 | $85.00M 10-Q · filed 2023-11-09 | $85.00M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | $85.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $85.00M 10-Q · filed 2023-08-08 | $85.00M derived: sum of 3 quarters · filed 2024-03-14 | $85.00M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | $0.00 derived: sum of 2 quarters · filed 2024-03-14 | $0.00 derived: sum of 3 quarters · filed 2024-03-14 | $0.00 derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $0.00 derived: sum of 2 quarters · filed 2024-03-14 | $0.00 derived: sum of 3 quarters · filed 2024-03-14 | $0.00 10-K · filed 2024-03-14 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $0.00 derived: sum of 2 quarters · filed 2022-11-07 | $0.00 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $0.00 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-07 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-03 | |||
| 2020-03-31 | $300.00M 10-Q · filed 2021-05-07 | |||
| 2019-09-30 | $0.00 10-Q · filed 2019-11-07 | |||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-11 | |||
| 2018-09-30 | $25.00M 10-Q · filed 2019-11-07 | |||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $25.00M 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | $25.00M 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |